ALC:SIXAlcon AG Analysis
Data as of 2026-03-10 - not real-time
$81.85
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Alcon Inc. (ALC) is trading around its 20‑day and 50‑day moving averages with a neutral trend and an RSI hovering near the midpoint, suggesting limited short‑term momentum. The MACD shows a bearish histogram, while price sits above a solid support near $78 and below resistance around $88, framing a modest upside potential of roughly 15% according to the model. Volatility over the past month is elevated at over 24%, yet the stock’s beta of ~0.74 points to lower systematic risk, and the market sentiment index reads “Extreme Greed,” indicating bullish sentiment may be overstretched.
Fundamentally, the company posts a trailing P/E well above the industry average, but a forward P/E near 21 and a modest forward EPS outlook soften the valuation concerns. The dividend yield is low at around 0.4% with a payout ratio under 20%, underscoring a sustainable payout backed by healthy operating and free cash flow. Upcoming Q4 earnings estimates and recent analyst coverage (median target ~$97) provide a catalyst, while the DCF‑derived fair value suggests the stock is not dramatically mispriced. Taken together, the balance of technical neutrality, growth‑oriented fundamentals, and a sustainable dividend supports a cautiously optimistic outlook.
Fundamentally, the company posts a trailing P/E well above the industry average, but a forward P/E near 21 and a modest forward EPS outlook soften the valuation concerns. The dividend yield is low at around 0.4% with a payout ratio under 20%, underscoring a sustainable payout backed by healthy operating and free cash flow. Upcoming Q4 earnings estimates and recent analyst coverage (median target ~$97) provide a catalyst, while the DCF‑derived fair value suggests the stock is not dramatically mispriced. Taken together, the balance of technical neutrality, growth‑oriented fundamentals, and a sustainable dividend supports a cautiously optimistic outlook.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Technical indicators are neutral with limited momentum
- Upcoming earnings could swing sentiment
- Current valuation is near fair value
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward earnings growth and improving forward P/E
- Sustainable dividend with low payout ratio
- Upside potential of ~15% based on valuation model
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong franchise in surgical and vision care markets
- Demographic tailwinds for eye‑care products
- Robust cash generation supporting reinvestment and dividends
Key Metrics & Analysis
Financial Health
Revenue Growth8.60%
Profit Margin9.42%
P/E Ratio41.3
ROE4.50%
ROA2.57%
Debt/Equity23.81
P/B Ratio1.8
Op. Cash Flow$2.3B
Free Cash Flow$1.2B
Industry P/E25.4
Technical Analysis
TrendNeutral
RSI48.7
Support$77.95
Resistance$87.64
MA 20$82.49
MA 50$80.97
MA 200$81.29
MACDBearish
VolumeStable
Fear & Greed Index77.41
Valuation
Fair Value$41.98
Target Price$94.41
Upside/Downside15.34%
GradeFair
TypeBlend
Dividend Yield0.41%
Risk Assessment
Beta0.74
Volatility24.35%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.